$PRLD SEC Filings

Filed On	Filing
10 Sep 2026	8-K: Regulation FD Disclosure Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
11 Aug 2026	10-Q
11 Aug 2026	8-K: Results of Operations and Financial Condition
08 Jul 2026	SCHEDULE 13G
10 Jun 2026	Form 4: Baker Bros. Advisors Lp, Director and 5 others Granted 76,000 Non-Qualified Stock Option (right to buy)
10 Jun 2026	Form 4: Dorton Katina, Director Granted 38,000 Director Stock Option (Right to Buy)
10 Jun 2026	Form 4: Babler Martin, Director Granted 38,000 Director Stock Option (Right to Buy)
10 Jun 2026	Form 4: Bonita David P, Director Granted 38,000 Director Stock Option (Right to Buy)
10 Jun 2026	Form 4: Sandor Victor, Director Granted 38,000 Director Stock Option (Right to Buy)
10 Jun 2026	Form 4: Friedman Paul A, Director Granted 38,000 Director Stock Option (Right to Buy)
10 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
12 May 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
12 May 2026	10-Q
04 May 2026	Form 4: Morris Charles Q, Chief Medical Officer Granted 450,000 Employee Stock Option (right to buy) ($2.12M)
29 Apr 2026	ARS
29 Apr 2026	DEFA14A
29 Apr 2026	Proxy statement: annual meeting on June 9, 2026 CEO pay $1.3M, down 42% · say-on-pay vote
28 Apr 2026	SCHEDULE 13G
28 Apr 2026	Form 4: Ra Capital MANAGEMENT, L.p., 10% owner and 3 others Disposed of 1,407,000 shares (Other Transaction) · Acquired 1,407,000 Pre-Funded Warrants (Right to Buy) (Other Transaction)
28 Apr 2026	Form 3: Ra Capital MANAGEMENT, L.p., 10% owner and 3 others Holds 7,882,882 shares of Common Stock

Comments